Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

The efficacy of oxygen therapy in reducing grey matter hypoxia and degeneration in an animal model of multiple sclerosis

EF 2018-19

Résumé
Multiple sclerosis (MS) is a chronic neurological disease that causes significant disability. This is due to an upregulated immune response involving inflammation that attacks the brain and spinal cord (central nervous system; CNS). An unrelenting loss of brain leads to a reduction in physical and mental abilities, greatly affecting the quality of life of people with MS. When brain oxygen levels are low (hypoxia), the upregulated immune response could worsen, leading to further impairment. Animal model and clinical patient data show that CNS hypoxia may contribute to MS disease progression. Therefore, treating hypoxia by administering oxygen therapy may reduce damage in the CNS. Although clinical trials of oxygen therapy were deemed unsuccessful, we believe that this was because levels of brain hypoxia could not be controlled for, and oxygen was given with no regard to current disease status. We believe that oxygen administered at the onset of an inflammatory event could reduce inflammation. We have preliminary data supporting this idea, which we want to investigate further before testing in patients. We will test the hypothesis that oxygen therapy can reduce brain hypoxia and injury in a mouse model of MS when therapy is started at the onset of inflammation. We will measure brain hypoxia, cell damage, and brain size in oxygen-treated groups and untreated groups using magnetic resonance imaging (MRI) and histology. We will compare behavioral test scores between groups to assess whether oxygen therapy can slow disease progression. This study will provide new data on the potential for oxygen to be used as a therapy in MS. If successful, we will re-open the door to this accessible therapy that could be combined with other current MS medications to improve outcome.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406282
Name
Evans Taelor
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The efficacy of oxygen therapy in reducing grey matter hypoxia and degeneration in an animal model of multiple sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Model; Atrophy; Behavior; Brain; Demyelination; Hypoxia; Inflammation; Mri; Multiple Sclerosis; Treatment
Abstract
Multiple sclerosis (MS) is a chronic neurological disease that causes significant disability. This is due to an upregulated immune response involving inflammation that attacks the brain and spinal cord (central nervous system; CNS). An unrelenting loss of brain leads to a reduction in physical and mental abilities, greatly affecting the quality of life of people with MS. When brain oxygen levels are low (hypoxia), the upregulated immune response could worsen, leading to further impairment. Animal model and clinical patient data show that CNS hypoxia may contribute to MS disease progression. Therefore, treating hypoxia by administering oxygen therapy may reduce damage in the CNS. Although clinical trials of oxygen therapy were deemed unsuccessful, we believe that this was because levels of brain hypoxia could not be controlled for, and oxygen was given with no regard to current disease status. We believe that oxygen administered at the onset of an inflammatory event could reduce inflammation. We have preliminary data supporting this idea, which we want to investigate further before testing in patients. We will test the hypothesis that oxygen therapy can reduce brain hypoxia and injury in a mouse model of MS when therapy is started at the onset of inflammation. We will measure brain hypoxia, cell damage, and brain size in oxygen-treated groups and untreated groups using magnetic resonance imaging (MRI) and histology. We will compare behavioral test scores between groups to assess whether oxygen therapy can slow disease progression. This study will provide new data on the potential for oxygen to be used as a therapy in MS. If successful, we will re-open the door to this accessible therapy that could be combined with other current MS medications to improve outcome.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Evans, Taelor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~